Business Description
Xtant Medical Holdings Inc
NAICS : 339112
SIC : 5047
ISIN : US98420P3082
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.24 | |||||
Equity-to-Asset | 0.55 | |||||
Debt-to-Equity | 0.46 | |||||
Debt-to-EBITDA | 4.64 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -0.37 | |||||
Beneish M-Score | -1.14 | |||||
WACC vs ROIC |
Growth Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -27.3 | |||||
3-Year EBITDA Growth Rate | -5.2 | |||||
3-Year EPS without NRI Growth Rate | 36.2 | |||||
3-Year FCF Growth Rate | -2.8 | |||||
3-Year Book Growth Rate | 28.2 | |||||
Future 3-5Y Total Revenue Growth Rate | 19.8 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 62.99 | |||||
9-Day RSI | 50.26 | |||||
14-Day RSI | 45.58 | |||||
6-1 Month Momentum % | -9.62 | |||||
12-1 Month Momentum % | 70.91 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.82 | |||||
Quick Ratio | 1.22 | |||||
Cash Ratio | 0.25 | |||||
Days Inventory | 259.5 | |||||
Days Sales Outstanding | 61.07 | |||||
Days Payable | 48.41 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -18.8 | |||||
Shareholder Yield % | -5.63 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 60.75 | |||||
Operating Margin % | -11.13 | |||||
Net Margin % | 0.72 | |||||
FCF Margin % | -12.06 | |||||
ROE % | 1.62 | |||||
ROA % | 0.88 | |||||
ROIC % | 11.82 | |||||
ROC (Joel Greenblatt) % | 4.9 | |||||
ROCE % | 3.41 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | N/A | |||||
PS Ratio | 1.21 | |||||
PB Ratio | 2.29 | |||||
Price-to-Tangible-Book | 3.44 | |||||
EV-to-EBIT | 74.22 | |||||
EV-to-EBITDA | 27.81 | |||||
EV-to-Revenue | 1.54 | |||||
EV-to-FCF | -12.33 | |||||
Price-to-Projected-FCF | 16.5 | |||||
Price-to-Median-PS-Value | 2.5 | |||||
Price-to-Net-Current-Asset-Value | 5.16 | |||||
Earnings Yield (Greenblatt) % | 1.35 | |||||
FCF Yield % | -8.9 |